Individual trials have established agent-specific evidence profiles, revealing differential cardiovascular efficacy within the GLP-1 RA class
Suspected adverse reactions to any medication should be reported via the MHRA Yellow Card Scheme (yellowcard.mhra.gov.uk)
The nonstatistical significances in this study were assigned due to the low dose of L-carnitine given and the subjects frailty status
So if carnitine is up in the group that got acetyl-carnitine and not in the group that got placebo, well, I think that pretty much confirms that this just didnt work. ALC for Treatment of Peripheral Neuropathy In the second trial, protocol ZHAOKE-2007L03540, investigators led by Dr
[PubMed] Johansen PB, Nowak J, Skjaerbaek C, Flyvbjerg A, Andreassen TT, Wilken M, Orskov H